Cloud-Based Drug Design and Development |
NEWS
|
|
Cloud Pharmaceuticals is enabling a paradigm shift to improve upon traditional drug discovery and design methods. We are breaking new ground in the field of “in silico” drug discovery – that is, performed on a computer or via computer modeling and simulation of molecules. Our Quantum Molecular Design process enables the rapid and accurate discovery of novel drug candidates. We seek partners at all stages of drug development, including early stage, preclinical, IND and Phase 1 and 2.
More Company > Our Approach
Cloud Pharmaceuticals uses an in silico process called Quantum Molecular Design to computationally design small molecules and peptides that inhibit the activity of protein targets. Quantum Molecular Design combines high-performance cloud computing, quantum mechanics/molecular mechanics (QM/MM), and molecular property simulation. This approach enables us to calculate accurate binding affinities in a fraction of the time and choose only molecules that could make a useful drug. Plus we’re able to identify novel drug candidates that exhibit low probability of toxic side effects and high probability of success.
We partner with pharma and biotech companies of all sizes as well as academic institutions who desire fast development of new matter as agonists or antagonists to their targets. More Science > Partnering PipelineCloud Pharmaceuticals is engaged in drug discovery and development programs spanning a wide range of indications including:
|
EVENTS
More Events > |
